Latest filings (excl ownership)
8-K
Submission of Matters to a Vote of Security Holders
14 Jun 24
8-K
Other Events
16 May 24
10-Q
2024 Q1
Quarterly report
9 May 24
8-K
Nuvalent Highlights Pipeline Progress, Reiterates Key Anticipated Milestones, and Reports First Quarter 2024 Financial Results
9 May 24
ARS
2023 FY
Annual report to shareholders
26 Apr 24
DEFA14A
Additional proxy soliciting materials
26 Apr 24
DEF 14A
Definitive proxy
26 Apr 24
S-8
Registration of securities for employees
27 Feb 24
10-K
2023 FY
Annual report
27 Feb 24
8-K
Nuvalent Highlights Pipeline Progress, Reiterates Key Anticipated Milestones and Reports Fourth Quarter and Full Year 2023 Financial Results
27 Feb 24
8-K
Nuvalent Announces “OnTarget 2026” Operating Plan and Key Anticipated Milestones
9 Jan 24
10-Q
2023 Q3
Quarterly report
14 Nov 23
8-K
Nuvalent Highlights Corporate and Pipeline Achievements and Reports Third Quarter
14 Nov 23
8-K
Nuvalent Announces Pricing of Public Offering of Common Stock
17 Oct 23
424B5
Prospectus supplement for primary offering
17 Oct 23
424B5
Prospectus supplement for primary offering
16 Oct 23
8-K
Nuvalent Reports Preliminary Phase 1 Clinical Data from ALKOVE-1 Trial
13 Oct 23
8-K
Other Events
4 Oct 23
10-Q
2023 Q2
Quarterly report
10 Aug 23
8-K
Nuvalent Highlights Pipeline Progress and Reports Second Quarter 2023 Financial Results
10 Aug 23
8-K
Amendments to Articles of Incorporation or Bylaws
16 Jun 23
10-Q
2023 Q1
Quarterly report
11 May 23
8-K
Nuvalent Announces Anticipated Timing of Preliminary Phase 1 Dose-Escalation Data for NVL-655 and Reports First Quarter 2023 Financial Results
11 May 23
ARS
2022 FY
Annual report to shareholders
28 Apr 23
DEF 14A
Definitive proxy
28 Apr 23
DEFA14A
Additional proxy soliciting materials
28 Apr 23
PRE 14A
Preliminary proxy
13 Apr 23
S-8
Registration of securities for employees
16 Mar 23
S-3ASR
Automatic shelf registration
16 Mar 23
10-K
2022 FY
Annual report
16 Mar 23
8-K
Nuvalent Highlights Pipeline and Business Progress and Reports Fourth Quarter and Full Year 2022 Financial Results
16 Mar 23
8-K
Regulation FD Disclosure
10 Mar 23
10-Q
2022 Q3
Quarterly report
10 Nov 22
8-K
Nuvalent Reviews Corporate and Pipeline Achievements and Reports Third Quarter 2022 Financial Results
10 Nov 22
8-K
Nuvalent Announces Pricing of Public Offering of Common Stock
1 Nov 22
424B5
Prospectus supplement for primary offering
1 Nov 22
424B5
Prospectus supplement for primary offering
1 Nov 22
424B5
Prospectus supplement for primary offering
31 Oct 22
8-K
Other Events
28 Oct 22
8-K
Departure of Directors or Certain Officers
6 Oct 22
Latest ownership filings
4
Matthew Shair
26 Jun 24
4
Emily Conley
18 Jun 24
4
James E Flynn
14 Jun 24
4
Andrew A. F. Hack
14 Jun 24
4
Cameron Wheeler
14 Jun 24
4
Joseph Pearlberg
14 Jun 24
4
Sapna Srivastava
14 Jun 24
4
Matthew Shair
14 Jun 24
4
Anna Protopapas
14 Jun 24
4
Michael L. Meyers
14 Jun 24
144
Notice of proposed sale of securities
14 Jun 24
4
Dwight Gary Gilliland
14 Jun 24
4
Emily Conley
14 Jun 24
4
Deborah Ann Miller
7 Jun 24
4
Matthew Shair
29 May 24
4
Emily Conley
17 May 24
SC 13G/A
Flynn James E
15 May 24
4
Matthew Shair
15 May 24
4
Matthew Shair
8 May 24
4
Deborah Ann Miller
3 May 24
4
Matthew Shair
1 May 24
4
Matthew Shair
24 Apr 24
4
Matthew Shair
17 Apr 24
4
Emily Conley
17 Apr 24
4
Matthew Shair
10 Apr 24
4
Deborah Ann Miller
5 Apr 24
4
Matthew Shair
3 Apr 24
SC 13D/A
Bain Capital Life Sciences Fund II, L.P.
29 Mar 24
4
Andrew A. F. Hack
29 Mar 24
4
Deborah Ann Miller
29 Mar 24
144
Notice of proposed sale of securities
28 Mar 24
144
Notice of proposed sale of securities
27 Mar 24
4
Matthew Shair
27 Mar 24
144
Notice of proposed sale of securities
25 Mar 24
4
Darlene Noci
25 Mar 24
144
Notice of proposed sale of securities
22 Mar 24
4
Emily Conley
19 Mar 24
144
Notice of proposed sale of securities
15 Mar 24
SC 13G/A
Paradigm Biocapital Advisors LP
14 Feb 24
SC 13G/A
Fairmount Funds Management LLC
14 Feb 24